Primary and metastatic breast cancer disease (2025 – CME) – online course
Description
Authors: J. Palussière and F. Orsi
Reviewers: F. Cornelis, D. Filippiadis, C. Nice, P. Reimer and G. M. Varano.
This course corresponds to chapter 2.2.5.3 Non-vascular interventional oncology in the European Curriculum and Syllabus for Interventional Radiology.
Abstract
Thermo-ablation (TA) use in breast cancers is a developing treatment.
After reviewing the different thermal ablation techniques used in breast cancers, we will discuss and analyze their indications in this particular frame, their limitations, the mode of subsequent imaging follow-up, and their results and potential complications.
In advanced-stage breast cancer, breast cancer liver metastases (BCLM) are a key factor affecting overall survival. Although metastatic breast disease is a systemic disease, with tumour deposits potentially spreading to different organs and tissues, and systemic therapy being the standard approach, local therapies for liver metastases in well-selected patients may play an important role in improving survival and quality of life. In this course, we will present the clinical and technical indications, along with their limitations, results, and potential complications in local IR treatment for BCLM.
Learning objectives
- Be aware of breast cancer and its histological and clinical different presentations
- Be aware of different available systemic therapies according to the molecular subtypes of breast cancer
- To know the available local and regional treatments
- Be aware of the indications of IR different therapies for breast cancer
- Be aware of the indications of IR local therapies in metastatic breast cancer
- Be confident with the techniques of percutaneous and intra-arterial therapies in metastatic breast cancer
- Know about post-procedural management and patient care
- Be aware of technical and clinical outcome
Further information
This course covers a basic level of IR knowledge and is designed for trainees, students or young consultants aiming to acquire essential knowledge or prepare for the EBIR exam. Thereby, it is tailored to the European Curriculum and Syllabus for IR and corresponds to chapter 2.2.5.3 Non-vascular interventional oncology.
The format of the course is interactive and easy to use, including texts, graphics, videos and a quiz to support your learning. The course duration is around one hour and is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to award 1 European CME credit (ECMEC). The CME accreditation for this course will expire on January 13, 2027. A non-CME accredited version of the course will remain available until January 13, 2029.
The acquired CME Certificate will be available in the myCIRSE area under CIRSE Academy.
The enrolment period of this course is linked to the validity of the All-Access Pass.
Release date: February 2025
